The emerging role of the molecular marker p27 in the differential diagnosis of adrenocortical tumors

Malignant adrenocortical tumors (ACTs) are rare and highly aggressive; conversely, benign tumors are common and frequently found incidentally (the so-called incidentalomas). Currently, the use of molecular markers in the diagnosis of ACTs is still controversial. The aim of this study was to analyze the molecular profile of different ACTs with the purpose of identifying markers useful for differentiating between these tumors. The ACTs that were studied (n=31) included nonfunctioning adenomas (ACAn)/incidentalomas (n=13), functioning adenomas with Cushing's syndrome (ACAc) (n=7), and carcinomas (n=11); normal adrenal glands (n=12) were used as controls. For each sample, the percentage area stained for the markers StAR, IGF2, IGF1R, p53, MDM2, p21, p27, cyclin D1, Ki-67, β-catenin, and E-cadherin was quantified using a morphometric computerized tool. IGF2, p27, cyclin D1, and Ki-67 were the markers for which the percentage of stained area was significantly higher in carcinoma samples than in adenoma samples. Ki-67 and p27 were the markers that exhibited the highest discriminative power for differential diagnosis between carcinomas and all type of adenomas, while IGF2 and StAR were only found to be useful for differentiating between carcinomas and ACAn and between carcinomas and ACAc respectively. The usefulness of Ki-67 has been recognized before in the differential diagnosis of malignant tumors. The additional use of p27 as an elective marker to distinguish benign ACTs from malignant ACTs should be considered.

[1]  Jinhwa Lee,et al.  The function of p27KIP1 during tumor development , 2009, Experimental & Molecular Medicine.

[2]  J. Lamb,et al.  The activities of cyclin D1 that drive tumorigenesis. , 2004, Trends in molecular medicine.

[3]  S. Shousha,et al.  High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Y. L. Bouc,et al.  Anomalies du système des IGFs dans les tumeurs cortico-surrénaliennes , 2001 .

[5]  T. Kamio,et al.  Immunoreactivity and receptor expression of insulinlike growth factor I and insulin in human adrenal tumors. An immunohistochemical study of 94 cases. , 1991, The American journal of pathology.

[6]  G. Arnaldi,et al.  Adrenal incidentaloma. , 2000, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[7]  G. Chrousos,et al.  p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. , 1994, The Journal of clinical endocrinology and metabolism.

[8]  U. Moll,et al.  The MDM2-p53 interaction. , 2003, Molecular cancer research : MCR.

[9]  M Reincke,et al.  ACTH-receptor expression, regulation and role in adrenocortial tumor formation. , 2001, European journal of endocrinology.

[10]  C. Cordon-Cardo,et al.  Adrenocortical Adenoma and Carcinoma: Histopathological and Molecular Comparative Analysis , 2003, Modern Pathology.

[11]  F. Tissier.  Classification of adrenal cortical tumors: what limits for the pathological approach? , 2010, Best practice & research. Clinical endocrinology & metabolism.

[12]  Michael J. Lee,et al.  The prevalence of adrenal incidentaloma in routine clinical practice , 2011, Endocrine.

[13]  A. Lacroix,et al.  Combined expression of BUB 1 B , DLGAP 5 , and PINK 1 as predictors of poor outcome in adrenocortical tumors : validation in a Brazilian cohort of adult and pediatric patients , 2011 .

[14]  N. Malek,et al.  p27kip1: a target for tumor therapies? , 2007, Cell Division.

[15]  M. Brennan,et al.  Adrenocortical carcinoma: Past, present, and future , 2012, Journal of surgical oncology.

[16]  C. Cordon-Cardo,et al.  Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  W. Young.  Clinical practice. The incidentally discovered adrenal mass. , 2007, The New England journal of medicine.

[18]  F. Beuschlein,et al.  Steroidogenic acute regulatory protein mRNA expression in adrenal tumours. , 2000, European journal of endocrinology.

[19]  H. Sasano,et al.  Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[20]  J. Manfredi.  The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. , 2010, Genes & development.

[21]  Jian Kuang,et al.  Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities , 2005, Oncogene.

[22]  P. Miccoli,et al.  Apoptosis control and proliferation marker in human normal and neoplastic adrenocortical tissues , 2002, British Journal of Cancer.

[23]  W. Miller.  Steroidogenic acute regulatory protein (StAR), a novel mitochondrial cholesterol transporter. , 2007, Biochimica et biophysica acta.

[24]  Paul G. Gauger,et al.  Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling , 2009, Clinical Cancer Research.

[25]  E. Medrano,et al.  High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas. , 1999, The Journal of investigative dermatology.

[26]  A. Gill,et al.  Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. , 2009, Endocrine-related cancer.

[27]  E. Papini,et al.  Mutational analysis of StAR gene in adrenal tumors , 2002, International journal of cancer.

[28]  A. Lacroix,et al.  Combined expression of BUB1B, DLGAP5, and PINK1 as predictors of poor outcome in adrenocortical tumors: validation in a Brazilian cohort of adult and pediatric patients. , 2012, European journal of endocrinology.

[29]  A. Worster,et al.  Understanding receiver operating characteristic (ROC) curves. , 2006, CJEM.

[30]  C. Gicquel,et al.  [Involvement of the IGF system in the pathogenesis of adrenocortical tumors]. , 2001, Annales d'endocrinologie.

[31]  E. Furth,et al.  Localization of the steroidogenic acute regulatory protein in human tissues. , 1997, The Journal of clinical endocrinology and metabolism.

[32]  J. Bertherat,et al.  Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. , 2005, Cancer research.

[33]  V. Rousson,et al.  IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours , 2006, Histopathology.

[34]  L. Weiss,et al.  The Weiss system for evaluating adrenocortical neoplasms: 25 years later. , 2009, Human pathology.

[35]  C. Cordon-Cardo,et al.  MDM2 and prognosis. , 2004, Molecular cancer research : MCR.

[36]  W. Young.  The incidentally discovered adrenal mass , 2007 .

[37]  Martin Fassnacht,et al.  Adrenocortical carcinoma: a clinician's update , 2011, Nature Reviews Endocrinology.

[38]  I. Saito,et al.  Expression profiles of COUP-TF, DAX-1, and SF-1 in the human adrenal gland and adrenocortical tumors: possible implications in steroidogenesis. , 2001, Molecular genetics and metabolism.

[39]  A. Khorram-Manesh,et al.  N-cadherin expression in adrenal tumors: Upregulation in malignant pheochromocytoma and downregulation in adrenocortical carcinoma , 2002, Endocrine pathology.